ANVS Stock — Annovis Bio Inc.: Cash, EV, Pipeline

Share price

$1.14

Market cap

$48.7M

Cash

$18.7M

Enterprise value

$30.0M

Balance sheet

Cash	$18.7M
Debt	$0.0M
Net cash	$18.7M
Enterprise value	$30.0M
Basic shares	42.6M shares
Fully diluted shares	51.3M shares
Fully diluted market cap	$58.5M
Cash per share	$0.44

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ANVS daily closes…

Loading price history…

Pipeline assets

buntanetap

Phase 3 · Active Modality: small molecule (oral)

Target neurotoxic aggregating proteins (APP, tau, α-synuclein; mRNA translational inhibition)

Indications

Alzheimer's disease (early AD) (Phase 3)
Parkinson's disease (PD) (Phase 3)
Parkinson's disease dementia (PDD) (Stage not disclosed)

Catalysts

— October 2026

Status note Lead product candidate. Pivotal Phase 3 early-AD trial (NCT06709014) fully enrolled with 860 patients as of July 2026. Phase 3 PD trial completed December 2023 (topline July 2024); OLE PD study initiated January 2026. FDA approved protocol for a pivotal Phase 3 in PDD (not yet initiated).

ANVS405

Preclinical · Active Modality: small molecule

Target neurotoxic aggregating proteins (mRNA translational inhibition)

Indications

Acute neurodegeneration, including traumatic brain injury (TBI) (Preclinical)

Status note Filing states plan is to seek funding to conduct toxicology and PK studies, file an IND, and proceed to Phase 1 safety/PK studies.

ANVS301

Phase 1 · Active

Target neurotoxic aggregating proteins (mRNA translational inhibition)

Partnerships National Institutes of Health (NIH): conducted and financed the completed single-ascending-dose Phase 1 trial

Indications

Advanced Alzheimer's disease (Phase 1)

Status note Completed single-ascending-dose Phase 1 trial, conducted and financed by NIH.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	buntanetap/posiphen
Lead indication	Early Alzheimers Disease
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06709014	Phase 3	Active, not recruiting	Sponsor	ANVS	—	Early Alzheimers Disease	—
NCT07284784	Phase 3	Recruiting	Sponsor	ANVS	—	Parkinson's Disease (PD); Deep Brain Stimulation	—
NCT07757204	Phase 3	Not yet recruiting	Sponsor	ANVS	—	Alzheimer's Dementia (AD)	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Annovis Bio Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ANVS — Annovis Bio Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials